Stock Events

Teva- Pharmaceutical Industries 

$17.28
343
+$0.18+1.05% Friday 20:00

Statistics

Day High
17.4
Day Low
17.07
52W High
17.69
52W Low
7.95
Volume
7,202,601
Avg. Volume
9,124,682
Mkt Cap
19.57B
P/E Ratio
-39.37
Dividend Yield
-
Dividend
-

Dividends

0%Dividend Yield
10Y Growth
N/A
5Y Growth
N/A
3Y Growth
N/A
1Y Growth
N/A

Earnings

8MayConfirmed
Q3 2022
Q4 2022
Q1 2023
Q2 2023
Q3 2023
Q4 2023
Q1 2024
0
0.33
0.67
1
Expected EPS
0.51
Actual EPS
0.48

People Also Follow

This list is based on the watchlists of people on Stock Events who follow TEVA. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Novartis
NVS
Mkt Cap244.62B
Novartis, through its Sandoz division, is a leading competitor in the generic pharmaceuticals market, directly challenging Teva's product lineup.
Pfizer
PFE
Mkt Cap163.88B
Pfizer, with its Upjohn division now merged into Viatris, competes in both the generic and branded pharmaceutical markets, overlapping with Teva's business areas.
Abbvie
ABBV
Mkt Cap300.69B
AbbVie competes with Teva in the specialty pharmaceutical sector, particularly in areas like biosimilars and branded pharmaceuticals.
Johnson & Johnson
JNJ
Mkt Cap360.71B
Johnson & Johnson, through its Janssen Pharmaceuticals division, competes in the branded pharmaceutical market, particularly in areas where Teva also operates.
Merck &
MRK
Mkt Cap323.59B
Merck competes with Teva in the development and marketing of branded pharmaceuticals, especially in therapeutic areas where Teva is active.
Gilead Sciences
GILD
Mkt Cap87.16B
Gilead Sciences competes with Teva in the specialty pharmaceuticals market, particularly in the antiviral sector where Teva also has a presence.
AMGEN
AMGN
Mkt Cap177.47B
Amgen competes with Teva in the biopharmaceutical sector, particularly in the development of biosimilars, a growing area of Teva's business.
Sanofi
SNY
Mkt Cap130B
Sanofi competes with Teva in both the branded and generic pharmaceutical markets, with a broad product portfolio that overlaps with Teva's.
Astrazeneca
AZN
Mkt Cap245.69B
AstraZeneca competes with Teva in the branded pharmaceutical sector, particularly in areas like respiratory and cardiovascular diseases where Teva is also active.

Analyst Ratings

18.33$Average Price Target
The highest estimate is $23.
From 6 ratings within the last 6 months. This is not an investment recommendation.
Buy
67%
Hold
33%
Sell
0%

About

Health Technology
Pharmaceuticals: Generic
Manufacturing
Pharmaceutical Preparation Manufacturing
Teva Pharmaceutical Industries Limited, a pharmaceutical company, develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, and internationally. The company offers sterile products, hormones, high-potency drugs, and cytotoxic substances in various dosage forms, including tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams. It also develops, manufactures, and sells active pharmaceutical ingredients. In addition, it focuses on the central nervous system, pain, respiratory, and oncology areas. Its products in the central nervous system include Copaxone for the treatment of relapsing forms of multiple sclerosis; AJOVY for the preventive treatment of migraine; and AUSTEDO for the treatment of tardive dyskinesia and chorea associated with Huntington disease. The company's products in the respiratory market comprise ProAir, QVAR, ProAir Digihaler, AirDuo Digihaler, and ArmonAir Digihaler, BRALTUS, CINQAIR/CINQAERO, DuoResp Spiromax, and AirDuo RespiClick/ArmonAir RespiClick for the treatment of asthma and chronic obstructive pulmonary disease. Its products in the oncology market include Bendeka, Treanda, Granix, Trisenox, Lonquex, and Tevagrastim/Ratiograstim. Teva Pharmaceutical Industries Limited has a collaboration MedinCell for the development and commercialization of multiple long-acting injectable products, a risperidone suspension for the treatment of patients with schizophrenia. The company was founded in 1901 and is headquartered in Tel Aviv-Yafo, Israel.
Show more...
CEO
Kaare Schultz
Employees
35001
Country
US
ISIN
US8816242098
WKN
000883035

Listings